ADMA Biologics was founded in 2004 and is headquartered in Ramsey, US

Director

Director

Chief Scientific and Medical Officer

Vice President, Chief Financial Officer

Director & Chairperson

Founder and Vice Chairman

ADMA Biologics has an office in Ramsey

Ramsey, US (HQ)

465 NJ-17

ADMA Biologics's revenue was reported to be $2.6 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 2.6 m |

## Net income (Q1, 2017) | (6.5 m) |

## EBIT (Q1, 2017) | (5.9 m) |

## Market capitalization (22-Aug-2017) | 47.5 m |

## Cash (31-Mar-2017) | 8.5 m |

ADMA Biologics's current market capitalization is $47.5 m.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 3.1 m | 5.9 m | 7.2 m | 10.7 m |

## Revenue growth, % | 93% | 21% | 49% | |

## R&D expense | 7.7 m | |||

## General and administrative expense | 8.5 m | |||

## Operating expense total | 16.2 m | |||

## EBIT | (15 m) | (16 m) | (15.5 m) | (17.3 m) |

## EBIT margin, % | (490%) | (271%) | (216%) | (163%) |

## Interest expense | 618.2 k | 1.3 m | 1.8 m | 2.2 m |

## Interest income | 7.6 k | 14.2 k | 37.8 k | 50.3 k |

## Pre tax profit | (15.5 m) | (17.4 m) | (18 m) | |

## Net Income | (15.5 m) | (16.8 m) | (18 m) | (19.5 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 1.5 m | 1.4 m | 1.5 m | 1.3 m | 1.9 m | 2.1 m | 2.3 m | 2.9 m | 2.6 m |

## R&D expense | 1.8 m | 1.5 m | 1.4 m | 1.5 m | 2.1 m | 2 m | 3.4 m | 1.7 m | 1.2 m |

## General and administrative expense | 1.5 m | 1 m | 1.3 m | 1.4 m | 2.1 m | 1.7 m | 1.7 m | 1.8 m | 4.3 m |

## Operating expense total | 3.3 m | 2.5 m | 2.7 m | 2.9 m | 4.2 m | 3.7 m | 5.1 m | 3.5 m | 5.5 m |

## EBIT | (3.6 m) | (3 m) | (3.2 m) | (3.5 m) | (4.7 m) | (4.2 m) | (5.5 m) | (3.7 m) | (5.9 m) |

## EBIT margin, % | (239%) | (222%) | (213%) | (268%) | (252%) | (196%) | (242%) | (127%) | (226%) |

## Interest expense | 342.8 k | 335.3 k | 476 k | 453.4 k | 449.3 k | 467.4 k | 538 k | 606 k | 618.5 k |

## Interest income | 3.6 k | 3.5 k | 5 k | 9.8 k | 11.1 k | 13.5 k | 12 k | 11.6 k | 18.6 k |

## Net Income | (4 m) | (3.4 m) | (3.6 m) | (4.7 m) | (5.1 m) | (4.6 m) | (6 m) | (4.3 m) | (6.5 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 26.1 m | 17.2 m | 10.4 m | 9.9 m |

## Accounts Receivable | 384 k | 924.5 k | 1 m | |

## Inventories | 1.7 m | 1.7 m | 3.4 m | 5 m |

## Current Assets | 31.1 m | 24.1 m | 21.3 m | 21.7 m |

## Total Assets | 32 m | 27.2 m | 23.7 m | 23.7 m |

## Accounts Payable | 2.7 m | 1.8 m | 2.1 m | 2.6 m |

## Total Debt | 6.1 m | |||

## Current Liabilities | 3.7 m | 4.2 m | 4.2 m | 11.2 m |

## Total Liabilities | 28.1 m | |||

## Additional Paid-in Capital | 74.2 m | 75.5 m | 88.2 m | 102.5 m |

## Retained Earnings | (52.6 m) | (69.4 m) | (87.4 m) | (106.9 m) |

## Total Equity | 21.6 m | 6 m | 821 k | |

## Debt to Assets Ratio | 0.3 x | |||

## Financial Leverage | 1.5 x | 4.5 x | 28.9 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 17.9 m | 14 m | 16.6 m | 7.8 m | 9.2 m | 8.9 m | 12.5 m | 7.9 m | 8.5 m |

## Accounts Receivable | 803.5 k | 562.2 k | 351.4 k | 522.5 k | 1.2 m | 944 k | 826.7 k | 1.3 m | 839.9 k |

## Inventories | 1.1 m | 1.5 m | 1.9 m | 2.5 m | 2.8 m | 4 m | 4.2 m | 4.6 m | 5.3 m |

## Current Assets | 26.5 m | 22.6 m | 31 m | 27.1 m | 25.2 m | 17.4 m | 29.5 m | 25.4 m | 15.7 m |

## Total Assets | 27.9 m | 25.3 m | 33.9 m | 29.8 m | 27.8 m | 19.7 m | 31.7 m | 27.5 m | 17.6 m |

## Accounts Payable | 2.3 m | 2.4 m | 1.8 m | 1.6 m | 2.2 m | 2.5 m | 3.3 m | 2.8 m | 3.9 m |

## Current Liabilities | 3.8 m | 4.1 m | 3.8 m | 3.2 m | 4.3 m | 4.3 m | 5.1 m | 9.2 m | 13 m |

## Additional Paid-in Capital | 74.8 m | 75.1 m | 86.5 m | 87.3 m | 87.8 m | 88.7 m | 102 m | 102.2 m | 102.7 m |

## Retained Earnings | (62.5 m) | (65.9 m) | (73.1 m) | (77.7 m) | (82.8 m) | (92 m) | (98 m) | (102.4 m) | (113.5 m) |

## Total Equity | 12.3 m | 9.2 m | 13.4 m | 9.5 m | 4.9 m | 3.9 m | (10.8 m) | ||

## Financial Leverage | 2.3 x | 2.7 x | 2.5 x | 3.1 x | 5.7 x | 8.1 x | -1.6 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (15.5 m) | (16.8 m) | (18 m) | (19.5 m) |

## Depreciation and Amortization | 247.9 k | 469.8 k | 469.6 k | |

## Accounts Receivable | (384 k) | (540.5 k) | (93.6 k) | |

## Inventories | 1.7 m | (39.7 k) | (1.7 m) | (1.6 m) |

## Accounts Payable | 2.7 m | (937.8 k) | 308.7 k | 476.8 k |

## Cash From Operating Activities | 13.6 m | (14.7 m) | (15.4 m) | (18.3 m) |

## Purchases of PP&E | (2.3 m) | (26.1 k) | (73.4 k) | |

## Cash From Investing Activities | (4 m) | (1.7 m) | 904.6 k | |

## Cash From Financing Activities | 9.8 m | 10.4 m | 16.8 m | |

## Interest Paid | 785.5 k | 1.3 m | 1.5 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (4 m) | (3.4 m) | (3.6 m) | (4.7 m) | (5.1 m) | (4.6 m) | (6 m) | (4.3 m) | (6.5 m) |

## Accounts Receivable | 803.5 k | 562.2 k | 351.4 k | 522.5 k | 1.2 m | 944 k | 826.7 k | 1.3 m | 839.9 k |

## Inventories | 1.1 m | 1.5 m | 1.9 m | 2.5 m | 2.8 m | 4 m | 4.2 m | 4.6 m | 5.3 m |

## Accounts Payable | 2.3 m | 2.4 m | 1.8 m | 1.6 m | 2.2 m | 2.5 m | 3.3 m | 2.8 m | 3.9 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 28.6 k |

## Financial Leverage | -1.6 x |

July 30, 2016

* CRL did not cite any concerns with clinical safety and
efficacy data for ri-002 submitted by adma in bla